Bumetanide

Bumetanide is an inhibitor of Na-K-2Cl cotransporter 1 (NKCC1, IC50 = 0.68 µM). It is selective for NKCC1 over NKCC2 (IC50 = 4 µM). Bumetanide is an agonist of G protein-coupled receptor 35 (GPR35, EC50 = 10 µM). It also inhibits various carbonic anhydrases. Bumetanide (0.1 mg/kg) increases urine flow and sodium and potassium excretion, as well as decreases sodium reabsorption, in anesthetized dogs. It reduces brain edema and infarct size in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO) when administered at doses ranging from 7.6 to 30.4 mg/kg. Formulations containing bumetanide have been used in the treatment of edema associated with congestive heart failure and hepatic and renal diseases.Formal Name: 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoic acid. CAS Number: 28395-03-1. Synonyms: PF-1593, Ro 10-6338. Molecular Formula: C17H20N2O5S. Formula Weight: 364.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 33 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 25 mg/ml, Ethanol: 14 mg/ml. lambdamax: 228, 262, 339 nm. SMILES: CCCCNC1=C(OC2=CC=CC=C2)C(S(N)(=O)=O)=CC(C(O)=O)=C1. InChi Code: InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23). InChi Key: MAEIEVLCKWDQJH-UHFFFAOYSA-N.